Navigation Links
Chindex-Fosun Pharma Joint Venture, Chindex Medical, To Participate in Acquisition of Alma Lasers; Fosun Pharma Increases Investment in Chindex Medical
Date:4/29/2013

BETHESDA, Md., April 29, 2013 /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX, "Chindex"), an American healthcare company providing healthcare services in China, today announced that Chindex Medical Limited ("CML"), its joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), has agreed to acquire approximately 36.17% of Alma Lasers, Inc. ("Alma") for approximately $53.5 million as part of a purchase by a group of buyers for substantially all of Alma. The buying group, which consists of CML, another subsidiary of Fosun Pharma and the Pramerica-Fosun China Opportunity Fund, would acquire substantially all of Alma indirectly through a jointly-owned entity. The total acquisition price by all buyers for Alma would be approximately $240 million, including indebtedness incurred at the Alma level, without recourse to CML.

In order to help fund the acquisition by CML of its interest in Alma, Fosun Pharma has agreed to invest approximately $41 million in cash in CML for additional equity in CML. Following such investment, CML, which currently is owned 51% by Fosun Pharma and 49% by Chindex, would be owned 70% by Fosun Pharma and 30% by Chindex. In connection with this investment Chindex has waived its participation in such investment and agreed to increase FosunPharma's board seats at CML from four of seven to five of eight.

Alma is a leading global medical energy-based (including lights, laser, radio frequency and ultrasonic) device manufacturer, with a comprehensive product offering and international sales network. Alma has developed leading R & D capabilities globally in the medical and aesthetic equipment manufacturing field and established a global brand in the market segment. Alma has an established record of sustained performance results. In 2012, Alma recorded nearly $100 million total revenue.

Roberta Lipson '/>"/>

SOURCE Chindex International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaceutical Market: Finland, Ireland, Denmark, Belgium, Cuba, Austria & Norway
2. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
3. Comprehensive Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
4. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
7. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
8. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
9. National Association of Specialty Pharmacy (NASP) Appoints Thomas Blissenbach, RPh, MS as a Member of The Board of Directors
10. Pharmacy Benefits Academy Heads West, May 13-14 in Portland
11. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... April 23, 2007 /PRNewswire-FirstCall/,Micromet, Inc. today announced ... collaboration with MedImmune, Inc. for the development,of ... validated tumor- associated antigen frequently expressed on,various ... 2007 Annual Meeting of the American Association ...
... 23, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... Linda University Medical Center showing,that one of ... an important role regulating the oxidative damage,induced ... alone or in combination with surgery,and chemotherapy ...
Cached Medicine Technology:Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 2Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 3Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 4Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3
(Date:9/19/2014)... 19, 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... patients to develop Type 2 diabetes continue to move ... U.S. District Court, District of South Carolina, Bernstein Liebhard ... September 12, 2014, discovery is underway and moving forward ... that Pfizer, Inc., the manufacturer of Lipitor, has produced ...
(Date:9/19/2014)... 2014 In partnership with Raw Beauty NYC, ... part of the project’s social media efforts. StudioPMG is honored ... re-define the perception of beauty as it applies to disabled ... idea by Shelly Baer and Vanessa Silberman, who wanted to ... and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina ...
(Date:9/19/2014)... Fla. Researchers at Jacksonville,s campus of Mayo Clinic ... they say contributes to both overproduction of toxic protein ... as well as loss of communication between neurons ... Their study, in the online issue of ... specific defect with drugs "may rejuvenate or rescue this ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... from 12 Days to 27 Hours , ... leading provider of Windows file server virtualization solutions, today ... for medical research and treatment, has deployed its AutoClone(TM) ... of its Windows data replication operations. Since its ...
... line to provide sun protection, laughs and college ... Today non-profit Cancer for College launches a ... All proceeds from the sunscreen sales will go ... in granting college scholarships to cancer survivors and ...
... COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: ... period under the Hart-Scott-Rodino Act for the collaboration and ... Merck affiliate for development and commercialization of vernakalant, an ... expired, and the agreement is now effective. , Under ...
... say the disease is no more dangerous than regular ... World Health Organization may declare a full-fledged swine flu ... has swept through Japan, a former WHO infectious disease ... occurring in a region outside North America, where a ...
... plating system offers zero-step locking mechanismHOFFMAN ESTATES, Ill., ... market introduction of the KINETIC-SL Dynamic Anterior Cervical ... from the U.S. Food and Drug Administration (FDA) ... cervical plating system and utilizes a ...
... DIEGO, May 19 /PRNewswire/ -- ... major advances in the development of their first-in-class, CK2 ... Wednesday, May 20th at 4:40 pm. William G. Rice, ... antitumor properties and tumor selectivity of CX-4945, the Company,s ...
Cached Medicine News:Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 2Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 3Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 4Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 2Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 5Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 6Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 7Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 8Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 9Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 10Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 11Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 12Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 13Health News:Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference 2